From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

OptiBiotix Health – 2023 results not as initially hoped, but trading performance is now fast-improving: STRONG BUY

By Tom Winnifrith & Steve Moore | Tuesday 2 July 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Developer of compounds to prevent and manage disease and promote wellness, OptiBiotix Health (OPTI) has announced results for the 2023 calendar year emphasising increased revenue and that it continues to see sales momentum building in 2024 with its highest ever single order of over £200,000 and sales orders in H1 approaching FY 2023. However, what about the bottom-line performance? And, with the shares currently around 16p, are they a buy, hold or sell?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Wednesday »

Tom

Are you coming to Sharestock on September 7?

 

VANL

Van Elle Holdings – a Buy?

Thursday »

CCT

Character Group – a Buy?

 

ING

Ingenta – now a Buy again?

 

Clown

Which PR genius wrote this?

 

HAT

H&T Group – now again a Buy

Time left: 01:36:27